Medibio Completes Heavily Oversubscribed Institutional Placement for $13.9 million to Accelerate Commercialisation | Be Korea-savvy

Medibio Completes Heavily Oversubscribed Institutional Placement for $13.9 million to Accelerate Commercialisation


(image: Korea Bizwire)

(image: Korea Bizwire)

press-release-notification

SYDNEY, Australia and MINNEAPOLIS, Oct. 12 (Korea Bizwire)Medibio Limited (ASX:MEB)(OTCQB:MDBIF) is pleased to announce that it has received firm commitments to raise $13.9 million via the placement of 38,736,640 ordinary shares at a price of $0.36 per share.  The placement will be conducted in a single tranche using the Company’s existing placement capacity under ASX Listing Rule 7.1 and 7.1A.

The funds will allow the Company to:

  • Build out organisational infrastructure for product commercialisation
  • Establish requirements and testing of products and products under development for future market verticals
  • Development of technology platform and infrastructure, including engineering capability, to support commercialisation
  • Position Medibio for regulatory approvals on future products

Aesir Capital Pty Ltd acted as Sole Lead Manager to the transaction.  

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.   The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA.  Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au.

Additional disclosure required by listing rule 3.10.5A
In accordance with listing rule 3.10.5A in relation to shares issued under the Company’s 7.1A capacity details of the placement are:

Effect of raising
The effect of the announced raising on the capital structure of the Company is set out below.

  Number Dilution
Shares currently on issue 156,196,558  
Placement    
Shares to be issued under LR7.1 placement capacity 23,141,984 14.82 %
Shares to be issued under LR7.1A placement capacity 15,594,656 9.98 %
Total Shares on issue after completion of the Placement 194,933,198 24.80 %

The Company believes the benefits from funds raised in this placement at a discount to the 15-day VWAP of 11.9% outweigh the inability of shareholders to participate.  The placement was not underwritten and direct costs of the raising are up to 7.5% of funds raised.

Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
jack.cosentino@medibio.com.au
T: +1 (952) 465 4787

Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231

Source: Medibio Limited via GLOBE NEWSWIRE

press release curation and disclaimer notice

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>